M. Kris

Oncology · 2000–2018

A researcher in the Science corpus: 34 papers; trusts 2 researchers and is trusted by 11 researchers here, as inferred from the citation graph.

Subfields

Whom M. Kris trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. William Pao

Who trusts M. Kris overall

  1. B. Chan
  2. William Pao
  3. Shang-Gin Wu
  4. Vincent A. Miller
  5. Adi F. Gazdar
  6. B. Hughes
  7. Jin-Yuan Shih
  8. J. Engelman
  9. H. Shigematsu

Papers from M. Kris's perspective

Ordered by how strongly the researchers M. Kris trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. (Cancer Research)
  2. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. (Proceedings of the National Academy of Sciences of the United States of America)
  3. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
  4. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor (Science)
  5. Mutations of the BRAF gene in human cancer (Nature)
  6. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib (Clinical Cancer Research)
  7. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF (Nature)
  8. Targeted cancer therapy (Nature)
  9. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. (Journal of Clinical Oncology)
  10. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M (Nature)

Their papers